Editorial by Prof Manolis Tsiknakis, Coordinator of ProCAncer-I project The ProCAncer-I project has completed the first year of its lifecycle at the end of October 2021. With this brief note key results and achievements of the first year are summarized in the sequel....
Newsletter #2
UC1: Detection of prostate cancer with high accuracy in both the peripheral and transitional zone
Within the ProCancer-I project, a total of nine clinical needs will be addressed utilizing artificial intelligence (AI) models trained on ProstateNET – a unified repository of 1.5 million images of prostate MRI acquired across the consortium. In the current landscape...
(Meta)Data Infrastructure for Trustworthy AI
ProCAncer-I aspires to create the largest interoperable, high-quality multi-parametric Magnetic Resonance Imaging (mpMRI) dataset worldwide/globally comprising more than 11.000 retrospective and more than 6.000 prospective mpMRI examinations, including clinical data,...
The clinical vision and impact of the project
Interview with prof. Daniele Regge (Clinical Coordinator of the ProCancer-I project) Q: In the case of prostate cancer there are several tests that can help clinicians in the decision process, for example, prediction algorithms based on PSA blood test and biopsy. Why...
A regulated pathway for Artificial Intelligence in Medical Imaging
A brief historical survey of European state-of-play, the open issues and the ProCAncer-I approach Over the last decade, Artificial Intelligence (AI) solutions to support the whole value-chain of medical imaging[1] has experienced a considerable acceleration. This...
Presentation of partner Fundacao D. Anna Sommer Champalimaud e Dr. Carloss Montez Champalimaud (CF)
By the Fundacao D. Anna Sommer Champalimaud e Dr. Carloss Montez Champalimaud (CF) Champalimaud Foundation (CF) is a private non-profit Portuguese institution, inaugurated in 2010 with the aim of advancing basic and translational world-leading research in...
Presentation of partner FUNDACION PARA LA INVESTIGACION DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA (HULAFE)
By the FUNDACION PARA LA INVESTIGACION DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA (HULAFE) The FUNDACION PARA LA INVESTIGACION DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA (HULAFE) is a Spanish non-profit organization that carries out...
Presentation of partner Massachusetts General Hospital (The General Hospital Corp) (QTIM)
By the Massachusetts General Hospital (The General Hospital Corp) (QTIM) Our lab, the Quantitative Translational Imaging in Medicine (QTIM) lab, at the Athinoula A. Martinos Center for Biomedical Imaging of the Massachusetts General Hospital (MGH), focuses on...
Newsletter #2 Contents
Highlights
ProCAncer-I at the ECR 2025 in Vienna
Jan 16, 2025
ProCAncer-I will organise a Dedicated Session on the project during the European Congress of Radiology 2025 on the 26th of February 2025, at 15.00-16.00, with the title "ProCAncer-I: an AI platform integrating multiparametric MRI and AI models" where we will present...
ProCAncer-I at the Healthcare Business Awards 2024
Dec 19, 2024
Harnessing Big Data for the Future of Healthcare: Innovative Solutions with EUCAIM, ProCAncer-I, and European Health Data Spaces
ProCAncer-I at the first EIT Health Morning Talks in Bosnia and Herzegovina
Dec 3, 2024
Harnessing Big Data for the Future of Healthcare: Innovative Solutions with EUCAIM, ProCAncer-I, and European Health Data Spaces
ProCAncer-I at the EMUC24 in Lisbon
Oct 1, 2024
The progress of major trials, the advent of artificial intelligence (AI), and interdisciplinary best practices were discussed at the 16th European Multidisciplinary Congress on Urological Cancers (EMUC24). The congress took place from the 7th to 10th of November 2024...